Wikidata

(Q62042058)

English

Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma

clinical trial

In more languages

Statements

short name
Perseus (English)
0 references
title
A Phase 3 Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects With Previously Untreated Multiple Myeloma Who Are Eligible for High-dose Therapy (English)
0 references
country
Australia
0 references
Belgium
0 references
Denmark
0 references
France
0 references
Greece
0 references
Italy
0 references
Netherlands
0 references
Norway
0 references
Poland
0 references
Spain
0 references
Switzerland
0 references
Turkey
0 references
start time
14 December 2018
0 references
end time
May 2029
0 references
number of participants
690
0 references
research intervention
dexamethasone acetate
0 references
(RS)-cyclophosphamide
0 references
(RS)-lenalidomide
0 references
daratumumab
0 references
thalidomide
0 references
bortezomib
0 references
minimum age
18 year
0 references
maximum age
70 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q62042058&oldid=2148527989"